Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Galectin Therapeutics Q3 EPS $(0.14), Same YoY

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share. This is unchanged from the same period last year.

byBenzinga Newsdesk

November 14, 2022

1 minute read

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share. This is unchanged from the same period last year.

B of A Securities Downgrades Applied Molecular to Underperform, Lowers Price Target to $0.5

By Benzinga Newsdesk

Today, 9:39 AM

B of A Securities analyst Jason Gerberry downgrades Applied Molecular (NASDAQ:AMTI) from Buy to Underperform and lowers the price target from $5 to $0.5.

AMTI

Market Volatility Rises Sharply After Powell’s Speech

By Lisa Levin

Today, 9:39 AM

U.S. stocks dropped sharply on Friday following comments from Federal Reserve Chief Jerome Powell.

AAPL

Founder Julie Wainwright Steps Down As RealReal’s CEO, Chairperson & Director

By Shivani Kumaresan

Today, 9:39 AM

RealReal Inc (NASDAQ:REAL) founder Julie Wainwright has decided to step down from her role as Chief Executive Officer, Chairperson, and member…

REAL

Earnings

Recap: L3Harris Technologies Q2 Earnings

By Benzinga Insights

Today, 9:39 AM

L3Harris Technologies (NYSE:LHX) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:30 PM. Here's what investors need to know about the announcement.

LHX

Galectin Therapeutics Q3 EPS $(0.14), Same YoY

Related Posts

B of A Securities Downgrades Applied Molecular to Underperform, Lowers Price Target to $0.5

Market Volatility Rises Sharply After Powell’s Speech

Founder Julie Wainwright Steps Down As RealReal’s CEO, Chairperson & Director

Recap: L3Harris Technologies Q2 Earnings